ACNT earnings analysis
What we found in ACNT's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ascent’s Q2 showed a sharp sales acceleration, with revenue up 37.6% year over year to $25.7 million and GAAP EPS improving to $0.07 from a prior-year loss. Operating results improved substantially, although gross margin declined to 21.6% and the Specialty Chemicals segment’s operating income fell to $0.6 million from $1.5 million as segment SG&A increased. Liquidity remains adequate with $28.1 million of cash and no revolver borrowings, but first-half operating cash use of $7.7 million and a $28.5 million total cash decline temper the improving earnings picture.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue accelerated 37.6% year over year
- Q2 net sales increased $7.0 million, or 37.6%, to $25.7 million year over year, driven by a 15.2% increase in pounds shipped and a 23.0% increase in average selling prices. Sales also rose from an implied $19.4 million in Q1 2026, based on $45.1 million of first-half revenue.
- Profitability materially improved
- GAAP net income from continuing operations was $0.7 million, versus a $2.4 million loss a year earlier, producing diluted EPS of $0.07. Consolidated operating loss narrowed to $0.3 million from $2.7 million, improving operating margin to -1.2% from -14.4%.
- Adjusted EBITDA turned positive
- Adjusted EBITDA turned positive at $1.5 million, or 5.7% of sales, from a $0.3 million loss, while SG&A declined $0.9 million to $5.5 million. Management attributed the SG&A decline principally to lower incentive bonus, professional fees, and repairs and maintenance.
- Specialty Chemicals delivered strong growth
- Specialty Chemicals sales were $25.7 million, up $7.0 million year over year. The Midwest Graphic Sales acquisition was described as earnings accretive from day one and ahead of schedule on integration.
- Liquidity remains supported by cash and revolver
- The company ended Q2 with $28.1 million of cash and cash equivalents, $17.9 million of unused revolver capacity, and no principal outstanding under credit facilities. The revolver commitment is $30.0 million and runs through December 31, 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Gross-margin compression persists
- Gross margin contracted 450 basis points year over year to 21.6%, despite gross profit increasing 14.0% to $5.5 million. For the first six months, gross margin was 18.5% versus 21.7%, indicating that sales growth has not fully translated into margin expansion.
- Working capital drove substantial cash use
- Cash used in operating activities was $7.7 million in the first six months of 2026. Accounts receivable and advances used $6.5 million of operating cash flow and inventory used $1.1 million, while cash, cash equivalents and restricted cash fell $28.5 million during the period.
- Material control weaknesses remain unremediated
- Disclosure controls were ineffective as of June 30, 2026 due to previously reported material weaknesses in internal control over financial reporting. The weaknesses, first identified in 2021 and 2022, remained unremediated as of June 30, 2026 because of continued IT general-control ineffectiveness.
- Tariff and input-cost uncertainty remains
- Management cited material inflation, tariffs, and global trade-policy changes as potential pressure on sales and profitability. A temporary 10% general tariff under Section 122 was imposed, and the company noted that it may not be able to offset all cost increases through pricing and savings actions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.07
- Gross margin
- 21.6%
- Operating margin
- -1.2%
- Segment
- Specialty Chemicals: $25.7 million of Q2 2026 sales, up $7.0 million (37.6%) year over year; segment operating income was $0.6 million versus $1.5 million.
What they said about what is next.
The 10-Q provided no quantitative revenue or EPS outlook. Management expects capital spending of as much as $3.0 million for the remainder of fiscal 2026 and believes $28.1 million of cash plus $17.9 million of revolver availability will fund operations and anticipated capital expenditures for the next 12 months and beyond.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 6, 2026
- Ascent Industries reported Q1 2026 results with revenue of $19.4 million, representing an 8.9% increase year-over-year. However, the company incurred a net loss of $2.1 million, resulting in an EPS of -0.21, amidst…
- 10-K · March 3, 2026
- Ascent completed its exit from the Tubular Products segment and is now a pure‑play Specialty Chemicals company, reporting continuing‑operations net sales of $74,942,000 and net income (including discontinued operations)…
- 10-Q · August 6, 2025
- Ascent Industries reported continuing‑operations revenue of $18,652,000 for the quarter (down from $21,468,000 a year ago and down vs prior quarter ~$25,000,000), with gross margin improving to 26.1% but operating…
- 10-K · March 4, 2025
- Ascent Industries Co. showed significant struggles in 2024 with a net loss of $13.6 million, attributed to a decline in revenue from $193.2 million in 2023 to $177.9 million in 2024, mainly affected by high operating…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACNT makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever